What changed in this filing

/stocks — the workspaceLOADING

Item 1. Business

2026-09-25 compared with 2025-09-29 · 333 added, 325 removed, 753 unchanged (47% of the section changed)

14 unchanged sentences

lead product candidate, PRP, is a variation upon our novel formulation and involves proenzymes, the inactive precursors of enzymes.

As a result of positive early indications of the anti-cancer effects of our technology, we have conducted successful pre-clinical

studies on PRP and commenced preparation for a clinical study in advanced cancer patients.

Subject to us receiving sufficient

financing, we plan to begin our Investigational Medicinal Product Dossier, study proposal and Investigator’s Brochure in 2025.

Our plan is to then commence our study preparation process with the contract research organization (“CRO”), analytical

lab and trial site(s) selection and to begin our clinical trial application for PRP (“CTA”) compilation in the first

calendar quarter of 2026 and complete the CTA compilation and submit the CTA in the first half of the 2026 calendar year.

second calendar quarter of 2026, we plan to begin the preparation of logistics and trial site initiation visits.

Subject to raising

additional sufficient capital, we subsequently plan to commence a First-In-Human (“FIH”), Phase Ib study in patients

with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in the second half of the 2026

calendar year, which study we hope to complete within twelve months thereafter.

We intend to develop our PRP to treat early-stage

cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing cancer based on genetic

a result of positive early indications of the anti-cancer effects of our technology, we have conducted successful pre-clinical studies

on PRP and commenced preparation for a clinical study in advanced cancer patients.

We have commenced preparation of our Clinical Study

Protocol and Investigator’s Brochure.

We have commenced our study preparation process with the contract research organization (“CRO”),

analytical lab and trial site(s) selection and begun our clinical trial application for PRP (“CTA”) compilation and plan

to submit the CTA in the fourth quarter of the 2026 calendar year.

In the first calendar quarter of 2027, we plan to begin the preparation

of logistics and trial site initiation visits.

Subject to raising additional sufficient capital, we subsequently plan to commence a First-In-Human

(“FIH”), Phase Ib study in patients with advanced solid tumors, evaluating the safety, pharmacokinetics and anti-tumor efficacy

of PRP in the first half of the 2027 calendar year, which study we hope to complete within twenty-four months thereafter.

develop our PRP to treat early-stage cancer and pre-cancerous diseases and as a preventative measure for patients at risk of developing

cancer based on genetic screening.

is an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention.

1 unchanged sentence

of pancreatic proenzymes, trypsinogen and chymotrypsinogen.

PRP produces multiple effects on cancerous cells intended to inhibit

tumor growth and potentially stop a tumor from spreading through the body.

PRP produces multiple effects on cancerous cells intended to inhibit tumor

growth and potentially stop a tumor from spreading through the body.

received notification from the U.S.

11 unchanged sentences

and its manufacture of the finished product for the Phase Ib clinical trial.

POP1 joint research and drug discovery program (“POP1 Program”) is designed to produce a backup clinical compound to PRP.

With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation between

lots and without sourcing the proenzymes from animals, we are undertaking a research project in collaboration with the universities of

Jaén and Granada.

We entered into a second two-year joint research and collaboration agreement with the University of Jaén,

which concluded successfully late 2024.

A third agreement is planned for the

next three years for future joint drug discovery research activities designed to produce a new compound which enhances the anti-cancer

effects of proenzymes and consequently introduces a new therapeutic drug class for the treatment and prevention of metastatic cancer.

occurs when cells in the body start to divide quickly and uncontrollably with an ability to migrate from one location and spread to

distant sites.

POP1 joint research and drug discovery program (“POP1 Program”) is designed to produce a backup clinical compound to

With the aim of producing large quantities of trypsinogen and chymotrypsinogen for commercial use, exhibiting minimal variation

between lots and without sourcing the proenzymes from animals, we are undertaking a research project in collaboration with the

universities of Jaén and Granada.

We entered into a second two-year joint research and collaboration agreement with the

University of Jaén, which concluded successfully in late 2024.

A third agreement is planned for the next two years for

future joint drug discovery research activities designed to produce a new compound which enhances the anti-cancer effects of

proenzymes and consequently introduces a new therapeutic drug class for the treatment and prevention of metastatic

occurs when cells in the body start to divide quickly and uncontrollably with an ability to migrate from one location and spread to distant

A cell becomes cancerous when it becomes undifferentiated.

The cell forgets to do its job and invests all its energy

in proliferating.

The cell forgets to do its job and invests all its energy in proliferating.

Unlike normal cells, cancer cells multiply, but do not differentiate.

3 unchanged sentences

goal is to stop cancer not by targeting tumor cell death but inducing cell differentiation.

This is known as differentiation

This is known as differentiation therapy.

The key focus is to convince the malignant cells to stop proliferating and return to do their work as a specific cell type.

Differentiation therapy does not target cell death, so healthy cells within the patient will not be compromised, unlike

chemotherapeutic drugs or gamma irradiation.

Differentiation

therapy does not target cell death, so healthy cells within the patient will not be compromised, unlike chemotherapeutic drugs or gamma

Differentiation

therapy induces the cancer cells into the pathway of terminal differentiation and eventual senescence ( i.e.

non-proliferative state).

Differentiation therapy acts not only against cancer cells but interestingly can turn cancer stem cells

(undifferentiated cells) towards completely differentiated ( i.e.

, a non-proliferative

Differentiation therapy acts not only against cancer cells but interestingly can turn cancer stem cells (undifferentiated cells)

towards completely differentiated ( i.e.

, normal) cells.

are natural elements within our body that could help us fight against cancer.

Enzymes are natural proteins that stimulate and

accelerate biological reactions in the body.

Particularly, enzymes secreted by the exocrine pancreas are essential for the digestion

of proteins and fats.

More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the

body’s primary defense against cancer and would be useful as a cancer treatment.

Since then, several scientists have endorsed

Professor Beard´s hypothesis with encouraging data from patient treatment.

Enzymes are natural proteins that stimulate and accelerate

biological reactions in the body.

Particularly, enzymes secreted by the exocrine pancreas are essential for the digestion of proteins

More than one hundred years ago, Professor John Beard first proposed that pancreatic enzymes represent the body’s primary

defense against cancer and would be useful as a cancer treatment.

Since then, several scientists have endorsed Professor Beard´s

hypothesis with encouraging data from patient treatment.

are developing a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis, the main cause

13 unchanged sentences

epithelial cancer cells to become invasive and stem cell-like, features which then allow these cancer cells to spread and metastasize.

PRP reverses the conversion from an epithelial to a mesenchymal phenotype and, as such, may reduce the metastatic potential of the tumor

PRP reverses the conversion from an epithelial to a mesenchymal phenotype and, as such, reduces the metastatic potential of the tumor

PRP also promotes the acquisition of a less malignant phenotype, in addition to a decrease in proliferation due to lineage (i.e.,

45 unchanged sentences

Of Clinical Studies

clinical efficacy of a suppository formulation containing bovine pancreatic pro-enzymes trypsinogen and chymotrypsinogen was evaluated

in the context of a UK Pharmaceuticals Special Scheme at the Dove Clinic in Hampshire, UK by Dr.

Julian Kenyon, the Company’s Chief

Scientific Officer, and the results were published by the Company in a peer-reviewed journal, Scientific Reports, on behalf of Dr.

Clinical effects were studied in 46 patients with advanced metastatic cancers of different origin (prostate, breast, ovarian, pancreatic,

colorectal, stomach, non-small cell lung, bowel cancer and melanoma) after treatment with a rectal formulation of both pancreatic pro-enzymes.

Patients were treated daily with a rectal formulation containing 8.92 mg of each of the two pancreatic pro-enzymes and 1.78 mg α-Amylase

(A) per suppository.

The study was carried out under a UK “Specials” License at the Dove Clinic, Hampshire, UK for periods

up to 14 months.

clinical efficacy of a suppository formulation containing bovine pancreatic pro-enzymes trypsinogen and chymotrypsinogen was

evaluated in the context of a UK Pharmaceuticals Special Scheme at the Dove Clinic in Hampshire, UK by Dr.

Julian Kenyon, the

Company’s former Chief Scientific Officer, and the results were published by the Company in a peer-reviewed journal,

Scientific Reports, on behalf of Dr.

Kenyon in 2008.

Clinical effects were studied in 46 patients with advanced metastatic cancers

of different origin (prostate, breast, ovarian, pancreatic, colorectal, stomach, non-small cell lung, bowel cancer and melanoma)

after treatment with a rectal formulation of both pancreatic pro-enzymes.

Patients were treated daily with a rectal formulation

containing 8.92 mg of each of the two pancreatic pro-enzymes and 1.78 mg α-Amylase (A) per suppository.

The study was carried

out under a UK “Specials” License at the Dove Clinic, Hampshire, UK for periods up to 14 months.

severe or serious adverse events related to the rectal administration were observed.

47 unchanged sentences

Whereas purification and yield of chymotrypsinogen is currently the focus of research.

synthetic version of trypsinogen and chymotrypsinogen could have additional benefits to the global healthcare system that could

further capitalize on the new therapeutic approach to treating cancer that PRP offers to cancer sufferers.

For example, both

proenzymes are synthesized by an in vivo (living organism) system to produce crystalized proteins that could be maintained for long

periods without suffering degradation, even in the absence of refrigeration.

This will be particularly useful for a longer shelf-life as well as global distribution of the drug product, particularly in warmer climates and developing regions where refrigeration

may not be available.

The program’s joint researchers at the universities of Jaén and Granada are currently

collaborating with the Institute of Microbiology and Microbial Biotechnology, at the University of Natural Resources and Life

Sciences in Vienna, Austria, and are working towards full scale manufacture of a synthetic recombinant formulation to

synthetic version of trypsinogen and chymotrypsinogen could have additional benefits to the global healthcare system that could further

capitalize on the new therapeutic approach to treating cancer that PRP offers to cancer sufferers.

For example, both proenzymes are synthesized

by an in vivo (living organism) system to produce crystalized proteins that could be maintained for long periods without suffering degradation,

even in the absence of refrigeration.

This will be particularly useful for a longer shelf-life as well as global distribution of the

drug product, particularly in warmer climates and developing regions where refrigeration may not be available.

The program’s joint

researchers at the universities of Jaén and Granada are currently collaborating with the Institute of Microbiology and Microbial

Biotechnology, at the University of Natural Resources and Life Sciences in Vienna, Austria, and are working towards full scale manufacture

of a synthetic recombinant formulation to PRP.

Target Indications

10 unchanged sentences

While the hope is that such procedures are curative,

in many instances the tumor returns, and second-line treatment strategies are chosen to achieve a degree of control over

In most instances, the benefit is temporary, and eventually the point is reached where the patient’s tumor either fails

to respond to treatment adequately, or the treatment has unacceptable toxicity that severely limits its usefulness.

the planned Phase I, II and III clinical trials confirm the efficacy of PRP, along with the favorable safety and tolerability

profile suggested by pre-clinical studies conducted to date, we believe our product will have utility in several clinical situations

in many instances the tumor returns, and second-line treatment strategies are chosen to achieve a degree of control over the tumor.

most instances, the benefit is temporary, and eventually the point is reached where the patient’s tumor either fails to respond

to treatment adequately, or the treatment has unacceptable toxicity that severely limits its usefulness.

the planned Phase I, II and III clinical trials confirm the efficacy of PRP, along with the favorable safety and tolerability profile

suggested by pre-clinical studies conducted to date, we believe our product will have utility in several clinical situations including:

the early-stage management of solid tumors, most likely as part of a multi-pronged treatment strategy in combination with existing

23 unchanged sentences

pancreatic cancer is an essentially fatal condition, disease duration is roughly equivalent to survival time.

The median time

of survival of patients with pancreatic cancer depends on the extend of disease at the time of diagnosis and ranges from 11 to 20

months for patients who qualified for surgical resection (Stage I/II), to 6-11 months for patients with locally advanced disease

(Stage III), and only two to six months for patients with metastatic disease (Stage IV) (Amikura 1995, Richter 2003).

low survival times into consideration, yearly incidence rates for pancreatic cancer are considered the more relevant measure for

this disease.

year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current

year and compiles the most recent data on cancer incidence, mortality, and survival.

Incidence data are collected by the National Cancer

Institute (NCI), the Centers for Disease Control and Prevention (CDC), and the North American Association of Central Cancer Registries

In 2020, it was estimated that a total of more than 1,806,590 new cancer cases and more than 606,520 cancer deaths occurred

in the United States according to the National Cancer Institute.

Amongst these, a total of almost 50,000 new cases of pancreatic cancer

(3.2% of new cancer cases) were estimated, which resulted in more than 40,000 deaths (8.2% of cancer deaths).

This means only 20% survival

rate of patients diagnosed with pancreatic cancer.

The median time of survival

of patients with pancreatic cancer depends on the extend of disease at the time of diagnosis and ranges from 11 to 20 months for patients

who qualified for surgical resection (Stage I/II), to 6-11 months for patients with locally advanced disease (Stage III), and only two

to six months for patients with metastatic disease (Stage IV) (Amikura 1995, Richter 2003).

Taking these low survival times into consideration,

yearly incidence rates for pancreatic cancer are considered the more relevant measure for this disease.

year the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the

current year and compiles the most recent data on cancer incidence, mortality, and survival.

Incidence data are collected by the

National Cancer Institute (NCI), the Centers for Disease Control and Prevention (CDC), and the North American Association of Central

Cancer Registries (NAACCR).

In 2025, it was estimated that a total of more than 2,041,910 new cancer cases were diagnosed and more

than 618,120 cancer deaths occurred in the United States according to the National Cancer Institute.

Amongst these, a total of

almost 67,530 new cases of pancreatic cancer (3.2% of new cancer cases) were estimated, which resulted in more than 52,740 deaths

(8.4% of cancer deaths).

This means only 21% survival rate of patients diagnosed with pancreatic cancer.

cancer is a generic term that can be used for any cancer involving the ovaries, arising from one of the several different cell types

5 unchanged sentences

This heterogeneity of the disease has impeded progress in the prevention, early detection, treatment and management of ovarian cancer.

2020, ovarian cancer is the eighth most diagnosed cancer among women in the world and accounts for an estimated 313,959 new cases and

207,252 deaths worldwide (World Cancer Research Fund International)., In the USA, 19,880 new cases (2015 – 2019) and 12,810 related

deaths (2016 – 2020) are estimated to occur (National Cancer Institute).

The disease typically presents at late stage when the

five-year relative survival rate is only 29%.

Few cases (15%) are diagnosed with localized tumor (stage 1), when the five-year survival

Strikingly, the overall five-year relative survival rate generally ranges between 30% to 40% across the globe and has seen

only very modest increases since 1995.

2022, ovarian cancer was the eighth most diagnosed cancer among women in the world and accounts for an estimated 324,603 new cases and

206,956 deaths worldwide (World Cancer Research Fund International).

In the United States, 21,010 new cases and 12,450 related deaths

are estimated to occur in 2026 (National Cancer Institute).

The disease typically presents at late stage when the five-year relative

survival rate is only 52%.

The earlier ovarian cancer is caught, the better chance a person has of surviving five years after being

For ovarian cancer, 21.7% are diagnosed at the local stage.

The 5-year relative survival for localized ovarian cancer is 91.9%.

are developing a therapeutic solution for the treatment of patients with advanced stages of cancer targeting solid tumors, which is cancer

5 unchanged sentences

therapeutic options for the treatment of cancer offer, at most, a few months of extra life or tumor stabilization.

believe that drugs that kill most tumor cells do not affect cancer stem cells, which can regenerate the tumor (e.g., chemotherapy).

Studies reveal the genetic changes in cells that cause cancer and spur its growth.

This research is providing scientific researchers

with many potential targets for drugs.

Some experts believe

that drugs that kill most tumor cells do not affect cancer stem cells, which can regenerate the tumor (e.g., chemotherapy).

Studies reveal

the genetic changes in cells that cause cancer and spur its growth.

This research is providing scientific researchers with many potential

targets for drugs.

Tumor cells, however, can develop resistance to drugs.

1 unchanged sentence

was developed because of the limitation of current cancer therapies.

While surgery is often safe and effective for early-stage

cancer, many standard therapies for late-stage cancer urgently need improvement;

current treatments generally provide modest

benefits and frequently cause significant adverse effects.

Our focus is to provide oncologists and their patients with therapies for

metastatic cancer which are more effective than current therapies, and which have a substantially reduced side effect

While surgery is often safe and effective for early-stage cancer,

many standard therapies for late-stage cancer urgently need improvement;

current treatments generally provide modest benefits and frequently

cause significant adverse effects.

Our focus is to provide oncologists and their patients with therapies for metastatic cancer which

are more effective than current therapies, and which have a substantially reduced side effect profile.

progress has been made within the oncology sector in developing new treatments, the overall cancer death rate has only improved by fifteen

58 unchanged sentences

Validation of the bioanalytical method will also be completed prior to lodging our first CTA,

which we plan to undertake at the Peter MacCallum Cancer Centre in Melbourne, Victoria, Australia’s largest cancer hospital.

are collaborating with CROs, manufacturing partners and consultants to complete activities prior to preparing the CTA for the Phase Ib

which we plan to undertake across investigator sites nationally across Australia.

We are collaborating with CROs, manufacturing partners

and consultants to complete activities prior to preparing the CTA for the Phase Ib study.

have received expressions of interest to evaluate proenzyme therapy as a method to prevent recurrence and metastasis of solid tumors

9 unchanged sentences

therapy in patients with advanced solid tumors is completed at the Peter MacCallum Cancer Centre.

Australia, we receive an up to 43.5% “cash-back” benefit in the form of a refund of our qualified research and, development

costs and expenses.

We received a refund of $0 and $196,937 AUD ($129,132) for the years ended June 30, 2025, and

2024, respectively.

Australia, we may receive an up to 43.5% “cash-back” benefit in the form of a refund of our qualified research and,

development costs and expenses subject to approval.

We received a refund of $0 for both periods for the years ended June 30, 2026,

and 2025, respectively.

We are continuing to evaluate all options to conduct our planned clinical trials in the most cost-efficient

5 unchanged sentences

be driven by the need to increase our internal resources in order to effectively manage our research and development activities.

second calendar quarter of 2025, we anticipate the submission of the CTA for PRP.

We anticipate receiving approval in the second

half of the 2025 calendar year.

Following the CTA approval, we plan to commence our study preparation process, including CRO Selection and

Contracts, Analytical Lab Selection Contracts and Trial Sites Selection and Contracts.

fourth quarter of 2026, we anticipate the submission of the CTA for PRP.

We anticipate receiving approval in the first quarter of

the 2027 calendar year.

Following the CTA approval, we plan to commence our study preparation process in collaboration with our appointed CRO, including selection of investigators and test sites.

In connection with the CTA, this product will

be part of our Investigation Medicinal Product Dossier, study protocol and Investigator’s Brochure.

In the second half of the

2025 calendar year, we hope to complete the study preparation process together with the Preparation of Logistics and Trial Sites

Initiation Visits and complete our CTA review.

Commencing in the second half of the 2025 calendar year, we intend to initiate a

Phase Ib study in advanced cancer patients with solid tumors and we anticipate costs to be approximately $6.5 million.

to raise additional financing to fund our planned Phase I, II and III clinical trials and for working capital.

2025 – April 2026

Investigational

Medicinal Product Dossier

be part of our study protocol and Investigator’s Brochure.

In the first quarter of the 2027 calendar year, we hope to complete

the study preparation process together with the Preparation of Logistics and Trial Sites Initiation Visits and complete our CTA

Commencing the second quarter of the 2027 calendar year, we intend to initiate a Phase Ib study in advanced cancer patients

with solid tumors, and we anticipate costs to be approximately $6.5 million.

We will need to raise additional financing to fund our

planned Phase I, II and III clinical trials and for working capital.

2025 – September 2026

Ib Clinical Study Protocol

Investigator’s

2026 – June 2026

2026 – August 2026

2026 – November 2026

2027 – February 2027

Research Organization and Contracts

2026 – June 2026

2027 – March 2027

Laboratory Selection and Contracts

Site Selection and Contracts

2026 – September 2026

2027 – March 2027

Site Initiation Visits

3 unchanged sentences

genetic and protein expression that occur in cancer cells because of being exposed to our proenzyme formulation.

The objective

of this work is to understand at the molecular level the targets of our proenzyme formulation, thereby providing the opportunity for

new, patentable drugs which can be developed further.

We plan to commence a targeted drug discovery program utilizing the identified

molecular target to search for novel anticancer agents.

The objective of this

work is to understand at the molecular level the targets of our proenzyme formulation, thereby providing the opportunity for new, patentable

drugs which can be developed further.

We plan to commence a targeted drug discovery program utilizing the identified molecular target

to search for novel anticancer agents.

POP1 Program has produced synthetic recombinant versions of the two proenzymes, trypsinogen and chymotrypsinogen.

14 unchanged sentences

initial focus is to organize, coordinate and finance the various parts of our drug development pipeline.

We intend to carefully

introduce new personnel into our Company over time as our R&D activities expand.

We plan for such personnel to have specific

expertise in product development, manufacture and formulation, regulatory affairs, toxicology, clinical operations and business

development (including intellectual property management, licensing and other corporate activities).

Additional clinical management

and development expertise will likely be required at the outset to assist with the development of PRP.

Therefore, we anticipate

hiring additional employees to effectively manage our contractors as our development activities progress.

We intend to carefully introduce

new personnel into our Company over time as our R&D activities expand.

We plan for such personnel to have specific expertise in product

development, manufacture and formulation, regulatory affairs, toxicology, clinical operations and business development (including intellectual

property management, licensing and other corporate activities).

Additional clinical management and development expertise will likely

be required at the outset to assist with the development of PRP.

Therefore, we anticipate hiring additional employees to effectively

manage our contractors as our development activities progress.

outsourcing strategy is common in the biotechnology sector and is an efficient way to obtain access to the necessary skills required

to progress a project, as the required skills change as the project progresses from discovery, through manufacturing and

non-clinical development and into clinical trials.

We anticipate that we will continue to use this model, thereby retaining the flexibility

to contract in the appropriate resource as and when required.

to progress a project, as the required skills change as the project progresses from discovery, through manufacturing and non-clinical

development and into clinical trials.

We anticipate that we will continue to use this model, thereby retaining the flexibility to contract

in the appropriate resource as and when required.

intend to seek and identify potential licensing partners for our product candidates as they progress through the various development

20 unchanged sentences

such other products have currently been made and it is unknown whether we will engage in any such discussion soon.

as we further develop PRP within the development pathway, we intend to assess future opportunities that may arise to use the expertise

of our management and scientific personnel for future prospective R&D projects.

However, as we further

develop PRP within the development pathway, we intend to assess future opportunities that may arise to use the expertise of our management

and scientific personnel for future prospective R&D projects.

are at a pre-revenue stage.

14 unchanged sentences

20.6 million new cancer cases and almost 10 million cancer deaths occurred in 2024.

Without urgent action, annual cancer cases are projected to rise to nearly

35 million by 2050.

As such, global demand for new cancer treatments

3 unchanged sentences

plan to target patients with solid tumors, most likely pancreatic and ovarian tumors, for whom other treatment options have been exhausted.

Globally these cancers resulted in over 673,255 deaths combined in 2020, according to the World Health Organization.

Globally these cancers resulted in over 674,365 deaths combined in 2022, according to the World Cancer Research Fund.

With such a high

mortality rate, a substantial unmet medical need exists for new treatments.

Once the efficacy and safety of PRP is demonstrated

in late-stage patient populations, we plan to undertake exploration of the utility of the drug in earlier stage disease, together with

investigation of the drug’s utility in other types of cancer.

Once the efficacy and safety of PRP is demonstrated in late-stage

patient populations, we plan to undertake exploration of the utility of the drug in earlier stage disease, together with investigation

of the drug’s utility in other types of cancer.

Market Potential

61 unchanged sentences

we agreed to pay five percent of each, and every license agreement subscribed for.

The contract may be cancelled at any time by

either party.

The contract may be cancelled at any time by either

To date, no amounts are owed under the agreement.

of Jaén Collaboration Agreement

have established a collaboration with the University of Jaén to carry out a research project aimed at the synthetic

development of PRP and its subsequent validation.

The University of Jaén is providing scientific research activities, the

Department of Health Sciences, which provides the necessary technical and human resources to carry out the programmed

A Collaboration Agreement (the “Collaboration Agreement”), dated October 1, 2020, was entered into with the main

objective for the synthetic development of PRP and its subsequent validation.

Pursuant to the Collaboration Agreement, a

pre-clinical protocol of safety evaluation was established relating to the antitumor efficacy on cancer stem cells and in orthotopic

xenotransplantations derived from cancer stem cells isolated from tumor cell lines, and newly developed synthetic formulation based

on the two pancreatic zymogens.

ownership of potential intellectual property rights that may arise because of the knowledge obtained through such research project

will belong to us.

In consideration for payment of compensation, the University of Jaén assigned and agreed to do all things

reasonably required to assign to the contracting entity all industrial property rights arising from such research project.

have established a collaboration with the University of Jaén to carry out a research project aimed at the synthetic development

of PRP and its subsequent validation.

The University of Jaén is providing scientific research activities, the Department of Health

Sciences, which provides the necessary technical and human resources to carry out the programmed works.

A Collaboration Agreement (the

“Collaboration Agreement”), dated October 1, 2020, was entered into with the main objective for the synthetic development

of PRP and its subsequent validation.

Pursuant to the Collaboration Agreement, a pre-clinical protocol of safety evaluation was established

relating to the antitumor efficacy on cancer stem cells and in orthotopic xenotransplantations derived from cancer stem cells isolated

from tumor cell lines, and newly developed synthetic formulation based on the two pancreatic zymogens.

ownership of potential intellectual property rights that may arise because of the knowledge obtained through such research project will

belong to us.

In consideration for payment of compensation, the University of Jaén assigned and agreed to do all things reasonably

required to assign to the contracting entity all industrial property rights arising from such research project.

return for ownership of the industrial property rights arising from such research project, we agreed to pay the University of Jaén

3 unchanged sentences

effect of pancreatic proenzymes against the tumor microenvironment and premetastatic niche.

The specific tasks developed under this

collaboration focused on the effects of PRP on cancer-associated fibroblasts within the tumor microenvironment.

Consistent with

existing rights, Propanc will own any intellectual property developed.

The personnel of the investigation team of the universities

of Jaén and Granada whose work has contributed to the creation of knowledge that gives rise to industrial property rights

should be listed as inventors.

Further, Professor Macarena Perán from the University of Jaén and Professor Marchal

from the University of Granada will receive one percent of the net revenue to us from sales of any products sold by us, or on our

behalf, which fall within the scope of protection of such industrial property rights.

The commencement date for the experiments was

September 1, 2022, and the estimated length of time for completion was 24 months.

The specific tasks developed under this collaboration

focused on the effects of PRP on cancer-associated fibroblasts within the tumor microenvironment.

Consistent with existing rights, Propanc

will own any intellectual property developed.

The personnel of the investigation team of the universities of Jaén and Granada

whose work has contributed to the creation of knowledge that gives rise to industrial property rights should be listed as inventors.

Further, Professor Macarena Perán from the University of Jaén and Professor Marchal from the University of Granada will

receive one percent of the net revenue to us from sales of any products sold by us, or on our behalf, which fall within the scope of

protection of such industrial property rights.

The commencement date for the experiments was September 1, 2022, and completed in June

third collaborative, two-year research project commenced in March of 2026, with the universities of Jaén and Granada undertaking

the evaluation of a senescence-modulating compound to mitigate gemcitabine-induced normal cell senescence in pancreatic cancer models.

The project will specifically evaluate the protective and senescence-modulating effects of PRP against gemcitabine-induced normal cell

senescence using in vitro and in vivo models of pancreatic cancer in the first year.

This will be expanded into the effects of PRP on

tissue rejuvenation and anti-aging by evaluating how PRP attenuates age-associated cellular senescence and promotes tissue rejuvenation

by fine-tuning TGF-β driven signaling networks, restoring cellular plasticity and reducing maladaptive stress responses.

The ownership

of potential industrial property rights that may arise as a result of the knowledge obtained through the project will belong to Propanc.

In consideration for payment of compensation, UJA and UGR hereby assign and agree to do all things reasonably required to assign to the

contracting entity all industrial property rights arising from the Project.

In return for ownership of the entire right and title in

all industrial property rights arising from the Project, Propanc agrees to pay the University of Jaén five percent (5%), and the

University of Granada five percent (5%), in both cases of the net sales of any products sold by Propanc which fall within the scope of

the protection of such industrial property rights.

This supersedes any previous royalty rates assigned to the University of Jaén

and the University of Granada, including any previously nominated individual employees, and also represents a maximum royalty rate to

be applied to any industrial property rights between the University of Jaén, the University of Granada and Propanc relating to

the use of PRP, whether sourced from animal derived, or synthetic recombinant materials, in the field of cancer, chronic diseases, or

any health conditions, including, but not limited to cell rejuvenation, anti-ageing, etc.

continue to learn the properties of proenzymes with the long-term aim of screening new compounds for development.

28 unchanged sentences

pharmaceutical composition and use of chymotrypsinogen or tripsinogen

ZL201710885368.4

pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen

ZL201080054056.5

pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a

selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

ZL201080054056.5

pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a

selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

ZL201710885368.4

pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen

Patent Convention

4 unchanged sentences

composition for treating cancer comprising trypsinogen and chymotrypsinogen

& Liechtenstein

Pharmaceutical

18 unchanged sentences

composition for treating cancer comprising trypsinogen and chymotrypsinogen

& Liechtenstein

Pharmaceutical

4 unchanged sentences

composition for treating cancer comprising trypsinogen and chymotrypsinogen

pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen

Pharmaceutical

composition for treating cancer comprising trypsinogen and chymotrypsinogen

pharmaceutical composition for treating cancer comprising trypsinogen and chymotrypsinogen

pharmaceutical composition comprising trypsinogen and chymotrypsinogen

10 unchanged sentences

selenium compound, a vanilloid compound and a cytoplasmic glycolysis reduction agent

MX/a/2017/009455

pharmaceutical composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a

16 unchanged sentences

a vanilloid compound and a cytoplasmic glycolysis reduction agent

States of America

Pharmaceutical

composition for treating cancer comprising trypsinogen and/or chymotrypsinogen and an active agent selected from a selenium compound,

a vanilloid compound and a cytoplasmic glycolysis reduction agent

by client (D)

201680070907.2

9 unchanged sentences

States of America